EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Exploratory findings about the prognostic value of baseline circulating trimethylated H3K27 nucleosomes in treatment-intent cohorts of non-small cell lung cancer

Marie Piecyk, Emmanuel Grolleau, Sara Calattini, Aurore Carrot, Gaelle Lescuyer, Audrey Gelot, Eloise Aubret, Justine Dubreuil, Virginie Pitiot, Margaux Raffin, Julie Balandier, Oriane Pelton und 5 weitere

Cancer Treatment and Research Communications · 2026-11 · 101541

DOI: 10.1016/j.ctarc.2026.101541 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Treatment and Research Communications, 2026-11. Verfasst von Marie Piecyk und 16 weiteren Autor:innen. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Information on the value of circulating methylated nucleosomes for predicting prognosis in non-small cell lung cancer (NSCLC) is limited. We sought to evaluate the association between circulating H3K27Me3-concentrations and overall survival (OS) and progression-free survival (PFS).

Methods

A retrospective analysis of plasma samples was performed using specimens collected from patients enrolled in the prospective ONCOPRO study (NCT03787056). Patients with NSCLC were classified into 3 cohorts: Curative intent (radiotherapy or surgery) with or without neoadjuvant treatment; Non-Curative first-line treatment including immunotherapy (NC-Imm); and Non-Curative first-line treatment without immunotherapy (NC-NonImm). Plasma H3K27Me3-nucleosome was quantified by an automated chemiluminescent immunoassay (Nu.Q® H3K27Me3).

Results

Sixty-four patients were included: Curative, n=19; NC-Imm; n=21; and NC-NonImm, n=24. Median follow-up ranged from 39.5–61.8 months across cohorts. Median baseline H3K27Me3-nucleosome concentrations were 9.54 ng/mL in the Curative cohort, 11.86 ng/mL in the NC-Imm cohort and 27.07 ng/mL in the NC-NonImm cohort (Curative vs NC-NonImm cohort, p=0.0027). In the NC-NonImm cohort, H3K27Me3-nucleosome levels below the median were associated with prolonged OS (hazard ratio [HR][95% confidence intervals] 0.11 [0.01-0.88], p=0.012). Lower H3K27Me3-nucleosome concentrations were also associated with prolonged PFS (HR 0.22 [0.04–1.08]; p=0.043).

Conclusion

These findings suggest a potential prognostic value for circulating H3K27Me3-nucleosomes in metastatic NSCLC. Larger studies are warranted to further validate and refine these observations.

Zitieren

APA

Piecyk, M., Grolleau, E., Calattini, S., Carrot, A., Lescuyer, G., Gelot, A., Aubret, E., Dubreuil, J., Pitiot, V., Raffin, M., Balandier, J., Pelton, O., Subtil, F., Duruisseaux, M., You, B., Payen, L., & Couraud, S. (2026). Exploratory findings about the prognostic value of baseline circulating trimethylated H3K27 nucleosomes in treatment-intent cohorts of non-small cell lung cancer. Cancer Treatment and Research Communications, 101541. https://doi.org/10.1016/j.ctarc.2026.101541

Vancouver

Piecyk M, Grolleau E, Calattini S, Carrot A, Lescuyer G, Gelot A, et al. Exploratory findings about the prognostic value of baseline circulating trimethylated H3K27 nucleosomes in treatment-intent cohorts of non-small cell lung cancer. Cancer Treatment and Research Communications. 2026:101541. doi:10.1016/j.ctarc.2026.101541

BibTeX
@article{Piecyk2026,
  author = {Piecyk, Marie and Grolleau, Emmanuel and Calattini, Sara and Carrot, Aurore and Lescuyer, Gaelle and Gelot, Audrey and Aubret, Eloise and Dubreuil, Justine and Pitiot, Virginie and Raffin, Margaux and Balandier, Julie and Pelton, Oriane and Subtil, Fabien and Duruisseaux, Michael and You, Benoît and Payen, Lea and Couraud, Sébastien},
  title = {Exploratory findings about the prognostic value of baseline circulating trimethylated H3K27 nucleosomes in treatment-intent cohorts of non-small cell lung cancer},
  journal = {Cancer Treatment and Research Communications},
  year = {2026},
  pages = {101541},
  doi = {10.1016/j.ctarc.2026.101541}
}
Kostenlos starten →